All In Biotech

Drug Trial Radar · NCT06252298

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

A Phase I Clinical Study Evaluating the Safety and Efficacy of SCTC21C in Participants With CD38+ Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

74

Planned (sponsor's estimate)

Start

Feb 28, 2024

Primary completion

Aug 28, 2025

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Feb 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies

Conditions

  • Relapsed or Refractory Hematologic Malignancies

Interventions

  • SCTC21CBiological

    SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs) and serious adverse event (SAE)Time frame: From the initiation of the first dose to the 45 days after the last dose
  2. The incidence of dose limiting toxicities (dose-finding stage)Time frame: Cycle 1 (28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital ,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.